Biopharmaceutical company Rein Therapeutics and core imaging laboratory Qureight have announced plans to collaborate on an idiopathic pulmonary fibrosis (IPF) clinical trial. 

The companies will integrate Qureight’s deep-learning platform into Rein’s planned Phase II trial of its lead asset LTI-03, a novel, multi-pathway, Caveolin-1-related peptide.  

Rein previously announced positive topline results from Cohort 2 (5mg BID) of the Phase Ib clinical trial of LTI-03 in IPF. 

In the trial, a positive trend was observed in seven out of eight biomarkers evaluated, with five biomarkers demonstrating dose-dependent effects and four biomarkers achieving statistical significance in the combined Cohort 1 and Cohort 2 data set. 

The Phase II clinical trial of LTI-03 will continue to evaluate the safety, tolerability and efficacy of LTI-03 in IPF across multiple biomarkers and measure lung function and healthy tissue regeneration.  

In the trial, Qureight will provide full end-to-end imaging core lab services, including site qualification, data handling, quality control and deep-learning AI image analysis, across 50 sites globally.  

Qureight’s deep-learning platform will be used to analyse lung imaging data and identify correlations between any volumetric changes within the lungs of IPF patients and LTI-03’s efficacy.  

AI tools will measure the volume of fibrotic, vascular and airway lung compartments, allowing a more detailed examination of LTI-03’s ability to simultaneously modulate pro-fibrotic activity and to protect critical alveolar epithelial cells. 

Brian Windsor, President and Chief Executive Officer of Rein Therapeutics, said: “We are taking the evaluation of biomarkers a step further with the application of cutting-edge deep-learning imaging technology and detailed AI-based data analysis by collaborating with Qureight on this Phase II trial. These tools will be critical in gaining a deeper understanding of the potential therapeutic effect of LTI-03.” 

Read the DDW interview with Dr Muhunthan Thillai, CEO at Qureight.

Diana Spencer, Senior Digital Content Editor, DDW